- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1199EUR$1,250USD£1,033GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Drug Pipelines
- July 2020
- 61 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Report
- April 2023
- 80 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Drug Pipelines
- March 2021
Global
From €1919EUR$2,000USD£1,653GBP
- Report
- April 2022
- 48 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Report
- June 2022
- 245 Pages
Global
From €3316EUR$3,456USD£2,856GBP
The House Dust Mite Allergy Drug market is a subset of the Allergy Drugs market. It is composed of drugs used to treat allergies caused by house dust mites, which are microscopic arthropods that live in house dust. These drugs are typically used to reduce symptoms such as sneezing, coughing, and itchy eyes. They may also be used to prevent the development of allergies in those who are at risk. Common drugs used to treat house dust mite allergies include antihistamines, corticosteroids, and immunotherapy.
The House Dust Mite Allergy Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi, Novartis, and Pfizer. Other companies include Allergan, AstraZeneca, Boehringer Ingelheim, and Teva Pharmaceuticals. Show Less Read more
